Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

No gains in efficacy observed by adding gemcitabine to adjuvant therapy for lymph node-positive breast cancer.

Barton MK.

CA Cancer J Clin. 2014 Jan-Feb;64(1):1-2. doi: 10.3322/caac.21206. Epub 2013 Nov 8. No abstract available.

PMID:
24436115
[PubMed - indexed for MEDLINE]
2.

Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.

Im SA, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW.

Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18.

PMID:
22094934
[PubMed - indexed for MEDLINE]
3.

Re: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

Cameron DA, Leonard RC.

J Natl Cancer Inst. 1999 Apr 21;91(8):728-9. No abstract available.

PMID:
10218517
[PubMed - indexed for MEDLINE]
Free Article
4.

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET.

J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60.

PMID:
9747866
[PubMed - indexed for MEDLINE]
Free Article
5.

Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.

Nielsen DL, Bjerre KD, Jakobsen EH, Cold S, Stenbygaard L, Sørensen PG, Kamby C, Møller S, Jørgensen CL, Andersson M.

J Clin Oncol. 2011 Dec 20;29(36):4748-54. doi: 10.1200/JCO.2010.33.9507. Epub 2011 Nov 14.

PMID:
22084374
[PubMed - indexed for MEDLINE]
Free Article
6.

Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?

Esteva FJ, Hortobagyi GN.

J Natl Cancer Inst. 2008 Apr 16;100(8):521-3. doi: 10.1093/jnci/djn098. Epub 2008 Apr 8. No abstract available.

PMID:
18398093
[PubMed - indexed for MEDLINE]
Free Article
7.

Role of gemcitabine in breast cancer management: an update.

Wirk B, Perez E.

Semin Oncol. 2006 Feb;33(1 Suppl 2):S6-14. Review.

PMID:
16472712
[PubMed - indexed for MEDLINE]
8.

[Adjuvant chemotherapy of early stage breast cancer].

Boér K.

Orv Hetil. 2010 Feb 28;151(9):344-53. doi: 10.1556/OH.2010.28824. Review. Hungarian.

PMID:
20159750
[PubMed - indexed for MEDLINE]
9.

Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.

Albain KS.

J Natl Cancer Inst. 2004 Dec 15;96(24):1801-4. No abstract available.

PMID:
15601631
[PubMed - indexed for MEDLINE]
Free Article
10.

[A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].

Yabe N, Murai S, Shimizu H, Kitasato K, Yoshikawa T, Oto I, Nakadai J, Jinno H, Kitagawa Y.

Gan To Kagaku Ryoho. 2013 Nov;40(12):2396-8. Japanese.

PMID:
24394124
[PubMed - indexed for MEDLINE]
11.

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.

Yardley D, Burris H 3rd, Peacock N, Raefsky E, Melnik M, Inhorn R, Shipley D, Hainsworth J.

Breast Cancer Res Treat. 2010 Sep;123(2):471-5. doi: 10.1007/s10549-010-1047-0. Epub 2010 Jul 24.

PMID:
20658263
[PubMed - indexed for MEDLINE]
12.

[Adjuvant chemotherapy based on evidence-based medicine for breast cancer patients].

Tokudome N, Ito Y.

Gan To Kagaku Ryoho. 2006 Mar;33(3):318-23. Review. Japanese.

PMID:
16531711
[PubMed - indexed for MEDLINE]
13.

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al.

N Engl J Med. 1994 May 5;330(18):1260-6. Erratum in: N Engl J Med 1994 Jul 21;331(3):211.

PMID:
7908410
[PubMed - indexed for MEDLINE]
Free Article
14.

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N.

J Natl Cancer Inst. 1998 Sep 16;90(18):1361-70.

PMID:
9747867
[PubMed - indexed for MEDLINE]
Free Article
15.

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.

Burstein HJ, Winer EP.

J Clin Oncol. 2009 Dec 1;27(34):5671-3. doi: 10.1200/JCO.2009.24.2222. Epub 2009 Nov 2. No abstract available.

PMID:
19884535
[PubMed - indexed for MEDLINE]
Free Article
16.

Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.

Partin JF, Mamounas EP.

Ann Surg Oncol. 2011 Nov;18(12):3399-406. doi: 10.1245/s10434-011-1698-z. Epub 2011 May 3.

PMID:
21537874
[PubMed - indexed for MEDLINE]
17.

[Chemotherapy for metastatic breast cancer].

Ito Y, Tokudome N.

Gan To Kagaku Ryoho. 2006 Jun;33(6):742-6. Review. Japanese.

PMID:
16770091
[PubMed - indexed for MEDLINE]
18.

Adjuvant therapy for early breast cancer: a time to refine.

Powles TJ.

J Natl Cancer Inst. 1997 Nov 19;89(22):1652-4. No abstract available.

PMID:
9390527
[PubMed - indexed for MEDLINE]
Free Article
19.

Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu.

Stein S, DeMichele A, Domchek S, Fox K.

Clin Breast Cancer. 2004 Jan;4 Suppl 3:S117-20. Review.

PMID:
14754469
[PubMed - indexed for MEDLINE]
20.

HER2 and response to paclitaxel in node-positive breast cancer.

Mehta R.

N Engl J Med. 2008 Jan 10;358(2):197-8; author reply 198. No abstract available.

PMID:
18193531
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk